Sep 19, 2019
NS2 Serves Partners with American Idol Singer-Songwriter Taylor Hicks for Concert Tour Benefiting Veteran IT Training and Employment Program
Jun 26, 2019
NS2 Serves to Auction Custom Jeep at Barrett-Jackson Auction
Jun 18, 2019
SAP NS2® Honored with 2019 Cogswell Award for Outstanding Industrial Security
Apr 15, 2019
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
Jan 02, 2019
Ascletis' IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA
Jan 01, 2019
Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu
Oct 18, 2018
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA
Oct 03, 2018
SAP NS2® to Hold 7th Annual Solutions Summit - "Era of Awareness"
Aug 06, 2018
Ascletis' Ravidasvir Recommended by WHO HCV Guidelines
Aug 01, 2018
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA
Jul 31, 2018
Ascletis Filed NDA for Its All-oral HCV Treatment
Jul 30, 2018
Veteran Training & Employment Program NS2 Serves Kicks Off Inaugural Course in Tampa
Jul 25, 2018
SeraCare Announces the Expansion of Their Proprietary AccuPlex(TM) Technology Product Portfolio with the Launch of the AccuSpan(TM) HCV RNA Linearity Panel
Jun 12, 2018
Ascletis Receives NDA Approval from China FDA for Ganovo
Oct 11, 2017
AbbVie Demonstrates Leadership in HCV with New MAVYRET(TM) (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
Sep 27, 2017
AbbVie Announces Approval of MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan
Sep 11, 2017
Janssen to Discontinue Hepatitis C Development Program
Aug 18, 2017
Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis
Aug 03, 2017
AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
Jul 28, 2017
European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)